Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

Saved in:
Bibliographic Details
Title: Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
Authors: Jiang H; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Torphy RJ; Department of Surgery, University of Colorado, Aurora, Colorado, USA., Steiger K; Institute of Pathology, School of Medicine, Technical University Munich and German Cancer Consortium (DKTK; partner site Munich), Munich, Germany., Hongo H; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Ritchie AJ; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Kriegsmann M; Department of Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Horst D; Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Umetsu SE; Department of Pathology, UCSF, San Francisco, California, USA., Joseph NM; Department of Pathology, UCSF, San Francisco, California, USA., McGregor K; Foundation Medicine, Cambridge, Massachusetts, USA., Pishvaian MJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Washington, DC, USA.; Perthera, Inc, McLean, Virginia, USA., Blais EM; Perthera, Inc, McLean, Virginia, USA., Lu B; Bristol-Myers Squibb, Summit, New Jersey, USA., Li M; Bristol-Myers Squibb, Summit, New Jersey, USA., Hollingsworth M; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA., Stashko C; Center for Bioengineering and Tissue Regeneration, UCSF, San Francisco, California, USA., Volmar K; Rex Healthcare., Yeh JJ; Lineberger Comprehensive Cancer Center.; Department of Surgery, and.; Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA. University of North Carolina, Chapel Hill, North Carolina, USA., Weaver VM; Center for Bioengineering and Tissue Regeneration, UCSF, San Francisco, California, USA., Wang ZJ; Department of Radiology and Biomedical Imaging, UCSF, San Francisco, California, USA., Tempero MA; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Weichert W; Institute of Pathology, School of Medicine, Technical University Munich and German Cancer Consortium (DKTK; partner site Munich), Munich, Germany., Collisson EA; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2020 Sep 01; Vol. 130 (9), pp. 4704-4709.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI136760